Skip to main content
Premium Trial:

Request an Annual Quote

Decode’s Genotyping Business Drives Double-Digit Growth in Q3 Revenues

NEW YORK (GenomeWeb News) - Decode Genetics yesterday said third-quarter revenues rose 27 percent while R&D spending was steady and net loss widened by 3 percent.
 
Total receipts for the three months ended Sept. 30 climbed to $10.9 million from $8.6 million year over year — an increase that the company attributed to its growing genotyping business.
 
R&D spending ticked down to $14.1 million from $14.2 million year over year.
 
Net loss increased to $24.3 million from $23.6 million in the year-ago period.
 
Decode said it had around $118.6 million in cash, cash equivalents, and investments as of Sept. 30.
 
Company CEO Kari Stefansson said Decode has continued to expand its DNA-based risk predisposition tests by launching an assay for myocardial infarction. Decode also plans to launch tests for other conditions, including one for glaucoma, in the near future.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.